About us
Belgium-based biotech company
Founded in 2018, Dendrogenix develop first-in-class molecules, Dendrogenins, to address high unmet medical needs in hearing loss and neurology
Technology
The origin of the discovery of our Dendrogenins results from the study of tamoxifen's mode of action through functional genomics studies. Tamoxifen has been the first drug used to treat hormone-dependent breast cancer. During metabolic and functional genomics studies associated with the activity of this drug, an ancillary pathway for Tamoxifen which is involved in the control of cell differentiation has been identified by Dr. Marc Poirot and his scientific team at the INSERM Institute in Toulouse. This pathway is based on serial sterol metabolism that generates molecules with original structures called Dendrogenins. These molecules stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors.
Our Team
We stay on top of our industry by being experts.
Board of Directors
Jean-Michel FOIDART
MD, PhD
CHAIRMAN OF THE BOARD
Stéphane SILVENTE
MBA
CO-FOUNDER
Philippe LEFEBVRE
MD, PhD
CO-FOUNDER
Emile LORIA (MD)
MEMBER OF THE BOARD
Patrick STRAGIER
NOSHAQ SPIN-OFFS REPRESENTATIVE
Caroline THIELEN (PhD)
SRIW REPRESENTATIVE